- Correction
- Open access
- Published:
Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
BMC Pharmacology and Toxicology volume 24, Article number: 49 (2023)
The Original Article was published on 10 October 2018
Correction to: BMC Pharmacol Toxicol 19, 63 (2018).
The original publication of this article did not provide clear clarification that the switch from brand to a generic drug was not done by the authors for the intention of the study. Patients were informed of the options and on switching to generic drugs the patients were able to expressed their agreements or disagreements, those who expressed their disagreement continued with their regimen.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s40360-018-0252-z.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Olalla, J., Pérez-Stachowski, J., Tortajada, B. et al. Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks. BMC Pharmacol Toxicol 24, 49 (2023). https://doi.org/10.1186/s40360-023-00693-8
Published:
DOI: https://doi.org/10.1186/s40360-023-00693-8